AlphaOS

ARGX

ARGENX SE

Healthcare · Biotechnology

$972.25Sep 28, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Strong evidence · 3 sources

Why it matters

ARGENX SE shows accelerating business momentum based on AlphaOS pipeline evidence, with strong management execution.

Why it matters: Revenue +75% YoY in Q4 FY2025.

TrajectoryAccelerating
ExecutionStrong
RiskMedium

1 signal not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Revenue +75% YoY in Q4 FY2025
  • Strong Product Sales Growth

Pipeline evidence · 0d ago

ARGX's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on ARGX.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest Intelligence

Updated

What happened recently for ARGENX SE (ARGX) — events, not interpretation.

Event
Last session September 28, 2026 at $972.25.
Source
Market data

Research & analysis only — not investment advice.

Loading earnings intelligence…

ARGENX SE (ARGX)

Healthcare · Biotechnology

Investment Snapshot above is the primary AlphaOS analysis for ARGENX SE — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Industry:
Biotechnology
Market cap:
$60.17B
Revenue:
$1.13B

ARGX earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow ARGENX SE through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Themes

ARGENX SE (ARGX) in AlphaOS research

Related & Connected

Related

Related stock research

Connected companies and research pages from the AlphaOS knowledge graph.